Ï㽶ÊÓƵ

Marcus M. Monroe
( out of 91 reviews )

Marcus M. Monroe, MD

Languages spoken: English
Request an Appointment Form

  • Marcus Monroe, M.D., is an associate professor in the Division of Otolaryngology—Head and Neck Surgery, Department of Surgery at the Ï㽶ÊÓƵ of Utah School of Medicine. He is a surgeon and investigator with the Huntsman Cancer Institute where he specializes in the complex multidisciplinary care of patients with head and neck cancer and serves as the Physician Lead for the Head and Neck Clinical Trials Program.

    His clinical practice involves treating patients with head and neck melanoma and nonmelanoma skin cancers, thyroid and parathyroid tumors, salivary gland tumors, and cancers of the upper aerodigestive tract (oral cavity, pharynx, larynx, and sinuses). Dr. Monroe believes that the best care comes when a team of specialists works together to create a treatment plan that is tailored to the individual patient. Because of this, he works closely with a team of cancer specialists, including medical and radiation oncologists, dermatologists, endocrinologists, pathologists, and radiologists to determine the best possible treatment for each patient.

    Dr. Monroe has published numerous articles and book chapters regarding cancers of the head and neck. His research interests include clinical trials for head and neck cancer, risk stratification in thyroid and advanced skin cancer, and survivorship issues following treatment for head and neck malignancies.

    Dr. Monroe received his medical degree at the Ï㽶ÊÓƵ of Missouri—Columbia School of Medicine and completed his residency training in Otolaryngology—Head and Neck Surgery at Oregon Health and Science Ï㽶ÊÓƵ (OHSU) in Portland, Oregon. Prior to joining the faculty at the Ï㽶ÊÓƵ of Utah, Dr. Monroe completed a 2-year fellowship in Head and Neck Surgical Oncology at the Ï㽶ÊÓƵ of Texas M.D. Anderson Cancer Center.

    Specialties

    Board Certification

    American Board of Otolaryngology

    Patient Rating

    5.0 /5
    ( out of 91 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 28, 2024
    HUNTSMAN CANCER CENTER

    Dr. Monroe and his staff are true professionals and kind and caring human beings. I have felt them in my corner through all of my treatment, and that has bolstered my courage through this illness.

    September 22, 2024
    HUNTSMAN CANCER CENTER

    I absolutely love my doctor. He is so kind understanding.

    September 16, 2024
    HUNTSMAN CANCER CENTER

    Please see & use my original comments. I am humbled and grateful to be in the care of Marcus and his team. He is a Rockstar!

    July 22, 2024
    HUNTSMAN CANCER CENTER

    Great doctor, very personable, and explains all procedures so you understand what your going to be experiencing. Show great concern when you are explaining things to him that are going on. His staff is very good as well.

    June 17, 2024
    HUNTSMAN CANCER CENTER

    Dr. Monroe is very kind personable, and very thorough. He is always patient, answering any questions you have. He is also open to having other family members attend appointments and answering all of their questions and concerns.

    June 17, 2024
    HUNTSMAN CANCER CENTER

    Explain all options and how we are going to proceed with treatment

    June 15, 2024
    HUNTSMAN CANCER CENTER

    He is an outstanding surgeon and excellent in explaining everything to you. He then provides you and opportunity to inquire about anything that may have been missed

    June 01, 2024
    HUNTSMAN CANCER CENTER

    Dr. Monroe did an excellent job. Recovery was quick and scar imperceptible.

    May 07, 2024
    HUNTSMAN CANCER CENTER

    I have been his patient for 6 1/6 yrs. I would not trade him for anyone else. He knows me and is very caring and supportive. He is a good listener and answers all my questions. I can send an email message or call him and I get a quick response. Thank you so much for being so good to me. You have a special place in my heart. Your medical team also has been supportive and caring. Thank you everyone...... Gracias!!!

    See More Patient Comments

  • Marcus Monroe, M.D., is an associate professor in the Division of Otolaryngology—Head and Neck Surgery, Department of Surgery at the Ï㽶ÊÓƵ of Utah School of Medicine. He is a surgeon and investigator with the Huntsman Cancer Institute where he specializes in the complex multidisciplinary care of patients with head and neck cancer and serves as the Physician Lead for the Head and Neck Clinical Trials Program.

    His clinical practice involves treating patients with head and neck melanoma and nonmelanoma skin cancers, thyroid and parathyroid tumors, salivary gland tumors, and cancers of the upper aerodigestive tract (oral cavity, pharynx, larynx, and sinuses). Dr. Monroe believes that the best care comes when a team of specialists works together to create a treatment plan that is tailored to the individual patient. Because of this, he works closely with a team of cancer specialists, including medical and radiation oncologists, dermatologists, endocrinologists, pathologists, and radiologists to determine the best possible treatment for each patient.

    Dr. Monroe has published numerous articles and book chapters regarding cancers of the head and neck. His research interests include clinical trials for head and neck cancer, risk stratification in thyroid and advanced skin cancer, and survivorship issues following treatment for head and neck malignancies.

    Dr. Monroe received his medical degree at the Ï㽶ÊÓƵ of Missouri—Columbia School of Medicine and completed his residency training in Otolaryngology—Head and Neck Surgery at Oregon Health and Science Ï㽶ÊÓƵ (OHSU) in Portland, Oregon. Prior to joining the faculty at the Ï㽶ÊÓƵ of Utah, Dr. Monroe completed a 2-year fellowship in Head and Neck Surgical Oncology at the Ï㽶ÊÓƵ of Texas M.D. Anderson Cancer Center.

    Board Certification and Academic Information

    Academic Departments Otolaryngology: Head & Neck Surgery -Primary
    Board Certification
    American Board of Otolaryngology

    Education history

    Fellowship Head and Neck Surgical Oncology - MD Anderson Cancer Center Fellow
    Otolaryngology - Oregon Health and Science Ï㽶ÊÓƵ Resident
    Internship Surgery - Oregon Health and Science Ï㽶ÊÓƵ Intern
    Medicine - Ï㽶ÊÓƵ of Missouri M.D.
    Undergraduate Biology and Chemistry Majors, Global Studies Minor - Drury Ï㽶ÊÓƵ B.A.

    Selected Publications

    Journal Article

    1. Anzai Y, Chang CP, Rowe K, Snyder J, Deshmukh V, Newman M, Fraser A, Smith K, Date A, Galvao C, Monroe M, Hashibe M (2023). Surveillance Imaging with PET/CT and CT and/or MRI for Head and Neck Cancer and Mortality: A Population-based Study. Radiology, 307(2), 212915. ()
    2. Amara Sarwal, Marcus Monroe, Dev Abraham, Tahir Zaman, Rama Kethineni, Nirupama Ramkumar, Josephine Abraham (2022). Acute Kidney Injury, Necrotizing Pancreatitis and Nephrocalcinosis:  An Uncommon Sequelae of Untreated Primary Hyperparathyroidism. Am J Kidney Dis, S62.
    3. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 20(6), 1-4. ()
    4. Highland J, Aylward A, Do O, Monroe M, Buchmann L (2021). Trust in physicians among patients with head and neck cancer before and after treatment. Head Neck, 43(9), 2580-2588. ()
    5. Dos Santos HT, Nam K, Hunt JP, Buchmann LO, Monroe MM, Baker OJ (2022). SPM Receptor Expression and Localization in Irradiated Salivary Glands. J Histochem Cytochem, 69(8), 523-534. ()
    6. Monroe M, Kakarala K (2021). Management of Advanced Basal Cell Carcinoma of the Head and Neck. Otolaryngol Clin North Am, 54(2), 271-280. ()
    7. Chang CP, Siwakoti B, Sapkota A, Gautam DK, Lee YA, Monroe M, Hashibe M (2019). Tobacco smoking, chewing habits, alcohol drinking and the risk of head and neck cancer in Nepal. Int J Cancer, 147(3), 866-875. ()
    8. Aylward A, Park J, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Rowe K, Snyder J, Deshmukh V, Newman M, Wan Y, Fraser A, Smith K, Lloyd S, Hitchcock Y, Hashibe M, Monroe MM (2020). Individualized prediction of late-onset dysphagia in head and neck cancer survivors. Head Neck, 42(4), 708-718. ()
    9. Kawakita D, Abdelaziz S, Chen Y, Rowe K, Snyder J, Fraser A, Smith K, Herget K, Deshmukh V, Newman M, Monroe M, Hashibe M (2019). Adverse respiratory outcomes among head and neck cancer survivors in the Utah Cancer Survivors Study. Cancer, 126(4), 879-885. ()
    10. Chen C, Lohavanichbutr P, Zhang Y, Houck JR, Upton MP, Abedi-Ardekani B, Agudo A, Ahrens W, Alemany L, Anantharaman D, Conway DI, Futran ND, Holcatova I, Gnther K, Hansen BT, Healy CM, Itani D, Kjaerheim K, Monroe MM, Thomson PJ, Witt BL, Nakoneshny S, Peterson LA, Schwartz SM, Zarins KR, Hashibe M, Brennan P, Rozek LS, Wolf G, Dort JC, Wang P (2019). Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples. Oral Oncol, 100, 104487. ()
    11. Lee YA, Al-Temimi M, Ying J, Muscat J, Olshan AF, Zevallos JP, Winn DM, Li G, Sturgis EM, Morgenstern H, Zhang ZF, Smith E, Kelsey K, McClean M, Vaughan TL, Lazarus P, Chen C, Schwartz SM, Gillison M, Schantz S, Yu GP, DSouza G, Gross N, Monroe M, Kim J, Boffetta P, Hashibe M (2019). Head and Neck Cancer Risk Prediction Models for the US Population from the INHANCE Consortium. Am J Epidemiol. ()
    12. Aylward A, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Lloyd S, Hitchcock Y, Hashibe M, Monroe MM (2019). Rates of Dysphagia-Related Diagnoses in Long-Term Survivors of Head and Neck Cancers. Otolaryngol Head Neck Surg, 161(4), 643-651. ()
    13. McCrary HC, Babajanian E, Calquin M, Carpenter P, Casazza G, Naumer A, Greenberg S, Kohlmann W, Cannon R, Monroe MM, Hunt JP, Buchmann L (2019). Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades. JAMA Otolaryngol Head Neck Surg, 145(7), 641-646. ()
    14. Cannon RB, Kull AJ, Carpenter PS, Francis S, Buchmann LO, Monroe MM, Lloyd S, Hitchcock YJ, Cannon D, Weis JR, Houlton JJ, Hunt JP (2019). Adjuvant radiation for positive margins in adult head and neck sarcomas is associated with improved survival: Analysis of the National Cancer Database. Head Neck, 41(6), 1873-1879. ()
    15. Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362. ()
    16. Cannon RB, Shepherd HM, McCrary H, Carpenter PS, Buchmann LO, Hunt JP, Houlton JJ, Monroe MM (2018). Association of the Patient Protection and Affordable Care Act With Insurance Coverage for Head and Neck Cancer in the SEER Database. JAMA Otolaryngol Head Neck Surg, 144(11), 1052-1057. ()
    17. Carpenter PS, Shepherd HM, McCrary H, Torrecillas V, Kull A, Hunt JP, Monroe MM, Buchmann LO, Cannon RB (10/1/18). Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction. JAMA Otolaryngol Head Neck Surg, 144(11), 988-994.
    18. Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kim J, Kirchhoff AC, Porucznik C, Hanson H, Abraham D, Monroe M, Hashibe M (2018). Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv, 12(5), 702-711. ()
    19. Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, Cannon D, Hitchcock YJ, Weis JR, Hunt JP, Houlton JJ, Cannon RB (2018). Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral Oncol, 85, 1-7. ()
    20. Park J, Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kirchhoff AC, Abraham D, Kim J, Monroe M, Hashibe M (2017). Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study. J Clin Endocrinol Metab, 103(7), 2468-2477. ()
    21. Cannon RB, Carpenter P, Boothe D, Buchmann LO, Hunt JP, Lloyd S, Hitchcock YJ, Houlton JJ, Weis JR, Shepard HM, Monroe MM (4/23/18). Academic Facility Utilization and Survival Outcomes in Adult Head and Neck Sarcomas: A NCDB Analysis. Otolaryngol Head Neck Surg, 2018(April), Epub Ahead.
    22. Dundar Y, Cannon RB, Hunt JP, Monroe M, Suneja G, Hitchcock YJ (2018). Radiotherapy regimens in patients with nonmelanoma head and neck skin cancers. Int J Dermatol, 57(4), 441-448. ()
    23. Hashibe M, Kirchhoff AC, Kepka D, Kim J, Millar M, Sweeney C, Herget K, Monroe M, Henry NL, Lopez AM, Mooney K (2018). Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah. Cancer Med, 7(4), 1490-1497. ()
    24. Orton A, Boothe D, Evans D, Lloyd S, Monroe MM, Jensen R, Shrieve DC, Hitchcock YJ (3/2018). Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database. Neurosurgery, 83(5), 940-947.
    25. Dundar Y, Cannon R, Wiggins R, Monroe MM, Buchmann LO, Hunt JP (3/1/18). Orbital invasion routes of non-melanoma skin cancers and survival outcomes. Orbit, Feb(21), 1-6.
    26. Maruyama CL, Monroe MM, Hunt J, Buchmann L, Baker OJ (2/8/18). Comparing Human and Mouse Submandibular Glands: A Practice Guide for Salivary Researchers. Oral Dis, 2018(Jan 30).
    27. Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kim J, Kirchhoff AC, Porucznik C, Hanson H, Monroe M, Hashibe M (2017). Aging-Related Disease Risks among Young Thyroid Cancer Survivors. Cancer Epidemiol Biomarkers Prev, 26(12), 1695-1704. ()
    28. Monroe MM, Hashibe M, Orb Q, Alt J, Buchmann LO, Hunt JP, Cannon-Albright LA (October 2017). Familial clustering of oropharyngeal squamous cell carcinoma in the Utah population. Head Neck, 40(2), 384-393.
    29. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (10/1/07). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477.
    30. Cannon RB, Dundar Y, Thomas A, Monroe MM, Buchmann LO, Witt BL, Sowder AM, Hunt JP (5/30/2017). Elective Neck Dissection for Head and Neck Cutaneous Squamous Cell Carcinoma with Skull Base Invasion. Otolaryngol Head Neck Surg, 156(4), 671-676.
    31. Hopkins Z, Witt BL, Monroe MM, Bowen GM, Bowen AR, Lloyd S (2017). Large, Nodulocystic Acneiform Eruption Following Radiotherapy for a Squamous Cell Carcinoma Recurrence in the Cervical Lymphatics. 1(1), 1-4.
    32. Dundar Y, Cannon RB, Monroe MM, Buchmann LO, Hunt JP (4/1/17). Skull Base Invasion Patterns and Survival Outcomes of NonMelanoma Skin Cancers. J Neurol Surg B Skull Base, 78(2), 164.
    33. Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Grossmann KF, Monroe MM (2/25/17). Treatment Related Determinants of Survival in Early Stage (T1-2N0M0) Oral Cavity Cancer – A Population-Based Study. Head Neck, 39(5), 876-880.
    34. Monroe MM, Buchmann LO, Hunt JP, Hashibe M (2017). The Benefit of Adjuvant Radiation in Surgically-Treated T1-2 N1 Oropharyngeal Squamous Cell Carcinoma. Laryngoscope Investig Otolaryngol, 2 February(2017).
    35. Cannon RB, Sowder JC, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Grossmann KF, Monroe MM (12/1/2016). Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study. Head Neck Surg, 39(1), 82-91.
    36. Orton A, Boothe D, Gan M, Monroe MM, Hitchcock YJ, Lloyd S (11/1/2016). The "decay" of brachytherapy use in tumors of the oral cavity: A population-based patterns of care and outcomes analysis from 1973 to 2012. Brachytherapy, 15(6), 851-858.
    37. Nam K, Maruyama CL, Trump BG, Buchmann LO, Hunt JP, Monroe MM, Baker OJ (6/1/2016). Post-Irradiated Human Submandibular Glands Display High Collagen Deposition, Disorganized Cell Junctions, and an Increased Number of Adipocytes. J Histochem Cytochem, 64(6), 343-352.
    38. Burt LM, Orlandi RR, Hunt JP, Buchmann LO, Grossman KF, Monroe MM, Shrieve DC, Hitchcock YJ (3/1/16). Function preservation and optimal outcomes—definitive chemoradiotherapy with multi-phase treatment planning for locally advanced sinonasal cancer. J Radiat Oncol, 5(1), 47-54.
    39. Monroe MM, Pattisapu P, Myers JN, Kupferman ME (2015). Sentinel Lymph Node Biopsy Provides Prognostic Value in Thick Head and Neck Melanoma. Otolaryngol Head Neck Surg, 153(3), 372-8. ()
    40. Lewis CM, Monroe MM, Roberts DB, Hessel AC, Lai SY, Weber RS (2015). An audit and feedback system for effective quality improvement in head and neck surgery: Can we become better surgeons? Cancer, 121(10), 1581-7. ()
    41. Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN (2015). Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther, 14(2), 608-19. ()
    42. Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N (11/1/14). Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg, 140(11), 1014-8.
    43. Monroe MM, Lai SY (2014). Sentinel lymph node biopsy for oral cancer: supporting evidence and recent novel developments. Curr Oncol Rep, 16(5), 385. ()
    44. Monroe MM, Myers JN, Kupferman ME (2013). Undertreatment of thick head and neck melanomas: an age-based analysis. Ann Surg Oncol, 20(13), 4362-9. ()
    45. Monroe MM, McLean M, Sautter N, Wax MK, Andersen PE, Smith TL, Gross ND (2013). Invasive fungal rhinosinusitis: a 15-year experience with 29 patients. Laryngoscope, 123(7), 1583-7. ()
    46. Chard R, Monroe MM, Andersen PE (2013). Hyoid osteoradionecrosis associated with carotid rupture: report of 2 cases. Head Neck, 35(2), E36-8. ()
    47. Monroe MM, Gross ND (2012). Evidence-based practice: management of the clinical node-negative neck in early-stage oral cavity squamous cell carcinoma. Otolaryngol Clin North Am, 45(5), 1181-93. ()
    48. Miller MW, Vetto JT, Monroe MM, Weerasinghe R, Andersen PE, Gross ND (2011). False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg, 145(4), 606-11. ()
    49. Monroe MM, McLean M, Gross ND (2011). Infected tracheal diverticulum presenting as a cervical abscess. Otolaryngol Head Neck Surg, 145(3), 513-4. ()
    50. Monroe MM, Cannady SB, Ghanem TA, Swide CE, Wax MK (2011). Safety of vasopressor use in head and neck microvascular reconstruction: a prospective observational study. Otolaryngol Head Neck Surg, 144(6), 877-82. ()
    51. Anderson EC, Hessman C, Levin TG, Monroe MM, Wong MH (2011). The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers (Basel), 3(1), 319-39. ()
    52. Monroe MM, Anderson EC, Clayburgh DR, Wong MH (2011). Cancer stem cells in head and neck squamous cell carcinoma. J Oncol, 2011, 762780. ()
    53. Monroe MM, McClelland J, Swide C, Wax MK (2010). Vasopressor use in free tissue transfer surgery. Otolaryngol Head Neck Surg, 142(2), 169-73. ()
    54. Monroe MM, Sauer DA, Samuels MH, Gross ND (2009). Pathology quiz case 1. Coexistent conventional mucoepidermoid carcinoma of the thyroid (MECT) and papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg, 135(7), 720, 722. ()

    Book Chapter

    1. Monroe MM, Sturgis EM (2017). Sarcomas and Soft Tissue Tumors of the Head and Neck. In Myers EN, Hanna E (Eds.), Cancer of the Head and Neck (5th Edition). Saunders.
    2. Casazza GC, Monroe MM (2016). Imaging Cutaneous Squamous Cell Carcinoma of the Head and Neck. In Hamblin, Avci, Gupta (Eds.), Imaging in Dermatology (ISBN: 978-0-12-802838-4) (1st Edition). San Diego: Elsevier.
    3. Monroe MM, Myers JN (2015). Targeted Therapy in Solid Tumors: Head and Neck (ISBN 978-1-118-46857-9). In Tsimberidou, Kurzrock, Anderson (Eds.), Targeted Therapy in Translational Cancer Research (1). Wiley.
    4. Monroe MM, Hessman C, Clayburgh D, Bubbers E, Wong ME (2001). Cancer Stem Cells in Solid Organ Malignancies: Mechanisms of Treatment Resistance and Strategies for Therapeutic Targeting. In Stanley Shostak (Ed.), Cancer Stem Cells (ISBN 978-953-307-1454-5).

    Commentary

    1. Monroe MM, Myers JN (2014). Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. . A Century of Progress in Head and Neck Cancer. Ed. Jatin Shah. Nat Med.

    Video/Film/CD/Web/Podcast

    1. Monroe MM (4/1/15). TalkAboutHealth: Head and Neck Cancer Questions and Answers [Web]. TalkAboutHealth. Available: http://talkabouthealth.com/MarcusMonroeMD.
    2. Ï㽶ÊÓƵ of Utah Office of Public Affairs (9/25/14). •Q&A: 3 Things to Know About Thyroid Cancer [Web]. Available: http://healthcare.utah.edu/healthfeed/postings/2014/09/092514_qa-thyroid-cancer.php.

  • News & Podcasts

    Podcasts